ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK; 2–5% of NSCLC) and ROS1 (1–3%) rearrangements represent another subset of oncogenic drivers in NSCLC for which there are multiple effective targeted agents.